1.Entinostat, a class I selective histone deacetylase inhibitor, plus exemestane for Chinese patients with hormone receptor-positive advanced breast cancer: A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial.
Binghe XU ; Qingyuan ZHANG ; Xichun HU ; Qing LI ; Tao SUN ; Wei LI ; Quchang OUYANG ; Jingfen WANG ; Zhongsheng TONG ; Min YAN ; Huiping LI ; Xiaohua ZENG ; Changping SHAN ; Xian WANG ; Xi YAN ; Jian ZHANG ; Yue ZHANG ; Jiani WANG ; Liang ZHANG ; Ying LIN ; Jifeng FENG ; Qianjun CHEN ; Jian HUANG ; Lu ZHANG ; Lisong YANG ; Ying TIAN ; Hongyan SHANG
Acta Pharmaceutica Sinica B 2023;13(5):2250-2258
		                        		
		                        			
		                        			Entinostat plus exemestane in hormone receptor-positive (HR+) advanced breast cancer (ABC) previously showed encouraging outcomes. This multicenter phase 3 trial evaluated the efficacy and safety of entinostat plus exemestane in Chinese patients with HR + ABC that relapsed/progressed after ≥1 endocrine therapy. Patients were randomized (2:1) to oral exemestane 25 mg/day plus entinostat (n = 235) or placebo (n = 119) 5 mg/week in 28-day cycles. The primary endpoint was the independent radiographic committee (IRC)-assessed progression-free survival (PFS). The median age was 52 (range, 28-75) years and 222 (62.7%) patients were postmenopausal. CDK4/6 inhibitors and fulvestrant were previously used in 23 (6.5%) and 92 (26.0%) patients, respectively. The baseline characteristics were comparable between the entinostat and placebo groups. The median PFS was 6.32 (95% CI, 5.30-9.11) and 3.72 (95% CI, 1.91-5.49) months in the entinostat and placebo groups (HR, 0.76; 95% CI, 0.58-0.98; P = 0.046), respectively. Grade ≥3 adverse events (AEs) occurred in 154 (65.5%) patients in the entinostat group versus 23 (19.3%) in the placebo group, and the most common grade ≥3 treatment-related AEs were neutropenia [103 (43.8%)], thrombocytopenia [20 (8.5%)], and leucopenia [15 (6.4%)]. Entinostat plus exemestane significantly improved PFS compared with exemestane, with generally manageable toxicities in HR + ABC (ClinicalTrials.gov #NCT03538171).
		                        		
		                        		
		                        		
		                        	
2.The analysis of long-term prognostic factors after laparoscopic liver resection for intrahepatic cholangiocarcinoma and establishment of survival Nomogram model.
Ze Feng SHEN ; Chen CHEN ; Zhi Min GENG ; Xian Hai MAO ; Jing Dong LI ; Tian Qiang SONG ; Chuan Dong SUN ; Hong WU ; Zhang Jun CHENG ; Rui Xin LIN ; Yu HE ; Wen Long ZHAI ; Di TANG ; Zhao Hui TANG ; Xiao LIANG
Chinese Journal of Surgery 2022;60(10):939-947
		                        		
		                        			
		                        			Objective: To establish a survival prediction model based on the independent prognostic factors of long-term prognosis after laparoscopic liver resection(LLR) for intrahepatic cholangiocarcinoma(ICC). Methods: The clinical and pathological data of 351 consecutive patients with ICC who received radical LLR in 13 Chinese medical centers from August 2010 to May 2021 were collected retrospectively. There were 190 males and 161 females,aged(M(IQR)) 61(14)years(range:23 to 93 years). The total cohort was randomly divided into a training dataset(264 cases) and a validation dataset(87 cases). The patients were followed up by outpatient service or telephone,and the deadline for follow-up was October 2021. Based on the training dataset,the multivariate Cox proportional hazards regression model was used to screen the independent influencing factors of long-term prognosis to construct a Nomogram model. The Nomogram model's discrimination,calibration,and clinical benefit were evaluated through internal and external validation,and an assessment of the overall value of two groups was made through the use of a receiver operating characteristic(ROC) curve. Results: There was no significant difference in clinical and pathological characteristics and long-term survival results between the training and validation datasets(all P>0.05). The multivariate Cox analysis showed that CA19-9,CA125,conversion to laparotomy during laparoscopic surgery,and lymph node metastasis were independent prognostic factors for ICC patients after LLR(all P<0.05). The survival Nomogram was established based on the independent prognostic factors obtained from the above screening. The ROC curve showed that the area under the curve of 1, 3 and 5-year overall survival rates of patients in the training dataset were 0.794(95%CI:0.721 to 0.867),0.728(95%CI:0.618 to 0.839) and 0.799(95%CI:0.670 to 0.928),and those in the validation dataset were 0.787(95%CI:0.660 to 0.915),0.831(95%CI:0.678 to 0.983) and 0.810(95%CI:0.639 to 0.982). Internal and external validation proved that the model exhibited a certain discrimination,calibration,and clinical applicability. Conclusion: The survival Nomogram model based on the independent influencing factors of long-term prognosis after LLR for ICC(including CA19-9,CA125,conversion to laparotomy during laparoscopic surgery,and lymph node metastasis) exhibites a certain differentiation,calibration,and clinical practicability.
		                        		
		                        		
		                        		
		                        			Bile Duct Neoplasms/surgery*
		                        			;
		                        		
		                        			Bile Ducts, Intrahepatic/pathology*
		                        			;
		                        		
		                        			CA-19-9 Antigen
		                        			;
		                        		
		                        			Cholangiocarcinoma/diagnosis*
		                        			;
		                        		
		                        			Female
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Laparoscopy
		                        			;
		                        		
		                        			Lymphatic Metastasis
		                        			;
		                        		
		                        			Male
		                        			;
		                        		
		                        			Nomograms
		                        			;
		                        		
		                        			Prognosis
		                        			;
		                        		
		                        			Retrospective Studies
		                        			
		                        		
		                        	
3.GKK1032B from endophytic Penicillium citrinum induces the apoptosis of human osteosarcoma MG63 cells through caspase pathway activation.
Na LIU ; Mei-Na SONG ; Qian-Qian ZHANG ; Cong WU ; Kong-Kai ZHU ; Yu-Lin SUN ; Meng-Ru LI ; Feng-Ying YANG ; Run-Liang FENG ; Yu-Ying ZHANG ; Hua ZHANG
Chinese Journal of Natural Medicines (English Ed.) 2022;20(1):67-73
		                        		
		                        			
		                        			Chemical investigation of the culture extract of an endophytic Penicillium citrinum from Dendrobium officinale, afforded nine citrinin derivatives (1-9) and one peptide-polyketide hybrid GKK1032B (10). The structures of these compounds were determined by spectroscopic methods. The absolute configurations of 1 and 2 were determined for the first time by calculation of electronic circular dichroism (ECD) data. Among them, GKK1032B (10) showed significant cytotoxicity against human osteosarcoma cell line MG63 with an IC50 value of 3.49 μmol·L-1, and a primary mechanistic study revealed that it induced the apoptosis of MG63 cellsvia caspase pathway activation.
		                        		
		                        		
		                        		
		                        			Apoptosis
		                        			;
		                        		
		                        			Bone Neoplasms
		                        			;
		                        		
		                        			Caspases
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Osteosarcoma/drug therapy*
		                        			;
		                        		
		                        			Penicillium
		                        			
		                        		
		                        	
4.Research on the lipid-lowering effect of traditional Chinese medicine using lipidomics technology
Mei-qin WANG ; Bing-ying HU ; Run-jing WANG ; Pan YAN ; Zhi-feng DU ; Hong-liang JIANG
Acta Pharmaceutica Sinica 2021;56(1):61-69
		                        		
		                        			
		                        			 Hyperlipidemia is a common disease with abnormal blood lipids and is an important risk factor for various cardiovascular diseases. Traditional Chinese medicine has the advantages of dependable lipid-lowering effects with few side effects and is widely used in the prevention and treatment of hyperlipidemia in China. However, due to the complex composition of traditional Chinese medicine and the many targets for treating hyperlipidemia, the mechanisms by which these medicines lower lipid levels are not well resolved. Lipidomics is a discipline that studies lipids and the interaction of lipids in biological systems. Lipidomics can identify and quantify the lipids 
		                        		
		                        	
5.Anatomical characteristics of patients with symptomatic severe aortic stenosis in China.
Tian-Yuan XIONG ; Yi-Ming LI ; Yi-Jun YAO ; Yu-Heng JIA ; Kai XU ; Zhen-Fei FANG ; Jun JIN ; Guo-Sheng FU ; Yi-Ning YANG ; Lei JIANG ; Wei-Dong LI ; Yan-Qing WU ; Yan-Song GUO ; Ran GUO ; Yun-Dai CHEN ; Yi LI ; Yi-Bing SHAO ; Yi ZHANG ; Bo-Sen YANG ; Yi-Ke ZHANG ; Jing-Jing HE ; Kai-Yu JIA ; Sheng-Hu HE ; Fa-Xin REN ; Jian-Cheng XIU ; Xing-Hua GU ; Liang-Long CHEN ; Ke HAN ; Yuan FENG ; Mao CHEN
Chinese Medical Journal 2021;134(22):2738-2740
6.Kinetic Characteristics of Neutralizing Antibody Responses Vary among Patients with COVID-19.
Ling Hua LI ; Hong Wei TU ; Dan LIANG ; Chun Yan WEN ; An An LI ; Wei Yin LIN ; Ke Qi HU ; Wen Shan HONG ; Yue Ping LI ; Juan SU ; San Tao ZHAO ; Wei LI ; Run Yu YUAN ; Ping Ping ZHOU ; Feng Yu HU ; Xiao Ping TANG ; Chang Wen KE ; Bi Xia KE ; Wei Ping CAI
Biomedical and Environmental Sciences 2021;34(12):976-983
		                        		
		                        			Objective:
		                        			The coronavirus disease 2019 (COVID-19) pandemic continues to present a major challenge to public health. Vaccine development requires an understanding of the kinetics of neutralizing antibody (NAb) responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
		                        		
		                        			Methods:
		                        			In total, 605 serum samples from 125 COVID-19 patients (from January 1 to March 14, 2020) varying in age, sex, severity of symptoms, and presence of underlying diseases were collected, and antibody titers were measured using a micro-neutralization assay with wild-type SARS-CoV-2.
		                        		
		                        			Results:
		                        			NAbs were detectable approximately 10 days post-onset (dpo) of symptoms and peaked at approximately 20 dpo. The NAb levels were slightly higher in young males and severe cases, while no significant difference was observed for the other classifications. In follow-up cases, the NAb titer had increased or stabilized in 18 cases, whereas it had decreased in 26 cases, and in one case NAbs were undetectable at the end of our observation. Although a decreasing trend in NAb titer was observed in many cases, the NAb level was generally still protective.
		                        		
		                        			Conclusion
		                        			We demonstrated that NAb levels vary among all categories of COVID-19 patients. Long-term studies are needed to determine the longevity and protective efficiency of NAbs induced by SARS-CoV-2.
		                        		
		                        		
		                        		
		                        			Adult
		                        			;
		                        		
		                        			Aged
		                        			;
		                        		
		                        			Aged, 80 and over
		                        			;
		                        		
		                        			Antibodies, Neutralizing/immunology*
		                        			;
		                        		
		                        			Antibodies, Viral/immunology*
		                        			;
		                        		
		                        			COVID-19/immunology*
		                        			;
		                        		
		                        			Female
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Kinetics
		                        			;
		                        		
		                        			Male
		                        			;
		                        		
		                        			Middle Aged
		                        			;
		                        		
		                        			Neutralization Tests
		                        			;
		                        		
		                        			SARS-CoV-2
		                        			
		                        		
		                        	
7.Prevalence, Risk Factors, and Psychological Effects of Primary Nocturnal Enuresis in Chinese Young Adults
Hui Jie HU ; Zhen Wei ZHANG ; Yu LIANG ; Yan Yan LUO ; Qi Feng DOU ; Cui Ping SONG ; Hui Min ZHANG ; Ying ZHAO ; Guang Run TIAN ; Ke ZHANG ; Qiu Fang MAO ; Jing Gui SONG ; Soren RITTIG ; Jian Guo WEN
International Neurourology Journal 2021;25(1):84-92
		                        		
		                        			Purpose:
		                        			This study aimed to investigate the prevalence, risk factors, and effects of primary nocturnal enuresis (PNE) on physical and mental health in young adults in mainland China. 
		                        		
		                        			Methods:
		                        			An anonymous questionnaire was used to collect information including the sociodemographic characteristics, history of PNE, family history, daytime voiding symptoms, Pittsburgh Sleep Quality Index (PSQI) scores, Self-Esteem Scale (SES), and Self-Rating Depression Scale (SDS). A total of 22,500 university students from 23 provinces and 368 cities in mainland China were included. 
		                        		
		                        			Results:
		                        			In total, 21,082 questionnaires were collected, and 20,345 of them qualified for statistical analysis. The PNE prevalence was 1.17%, and the distribution of monosymptomatic nocturnal enuresis (MNE) and nonmonosymptomatic nocturnal enuresis (NMNE) was 66.1% and 33.9%, respectively. In total, 28% of respondents with PNE reported bedwetting daily, 31.6% between 1 and 7 times weekly, and 40.4% between 1 and 4 times monthly; 80% of PNE cases had no history of treatment. The prevalence of PNE in patients with a family history, frequency, urgency, urinary incontinence, and recurrent urinary tract infections was significantly higher than in those without these conditions (P<0.001). PNE was significantly correlated with the PSQI total score (sleep quality) (P=0.011). The SES score was lower and the SDS was higher (P<0.001) in the PNE group than in those without PNE. 
		                        		
		                        			Conclusions
		                        			In mainland China, the PNE prevalence among young adults was found to be high, and PNE had significant effects on physical and mental health. Risk factors included a family history, daytime voiding symptoms, and lack of treatment.
		                        		
		                        		
		                        		
		                        	
8.Prevalence, Risk Factors, and Psychological Effects of Primary Nocturnal Enuresis in Chinese Young Adults
Hui Jie HU ; Zhen Wei ZHANG ; Yu LIANG ; Yan Yan LUO ; Qi Feng DOU ; Cui Ping SONG ; Hui Min ZHANG ; Ying ZHAO ; Guang Run TIAN ; Ke ZHANG ; Qiu Fang MAO ; Jing Gui SONG ; Soren RITTIG ; Jian Guo WEN
International Neurourology Journal 2021;25(1):84-92
		                        		
		                        			Purpose:
		                        			This study aimed to investigate the prevalence, risk factors, and effects of primary nocturnal enuresis (PNE) on physical and mental health in young adults in mainland China. 
		                        		
		                        			Methods:
		                        			An anonymous questionnaire was used to collect information including the sociodemographic characteristics, history of PNE, family history, daytime voiding symptoms, Pittsburgh Sleep Quality Index (PSQI) scores, Self-Esteem Scale (SES), and Self-Rating Depression Scale (SDS). A total of 22,500 university students from 23 provinces and 368 cities in mainland China were included. 
		                        		
		                        			Results:
		                        			In total, 21,082 questionnaires were collected, and 20,345 of them qualified for statistical analysis. The PNE prevalence was 1.17%, and the distribution of monosymptomatic nocturnal enuresis (MNE) and nonmonosymptomatic nocturnal enuresis (NMNE) was 66.1% and 33.9%, respectively. In total, 28% of respondents with PNE reported bedwetting daily, 31.6% between 1 and 7 times weekly, and 40.4% between 1 and 4 times monthly; 80% of PNE cases had no history of treatment. The prevalence of PNE in patients with a family history, frequency, urgency, urinary incontinence, and recurrent urinary tract infections was significantly higher than in those without these conditions (P<0.001). PNE was significantly correlated with the PSQI total score (sleep quality) (P=0.011). The SES score was lower and the SDS was higher (P<0.001) in the PNE group than in those without PNE. 
		                        		
		                        			Conclusions
		                        			In mainland China, the PNE prevalence among young adults was found to be high, and PNE had significant effects on physical and mental health. Risk factors included a family history, daytime voiding symptoms, and lack of treatment.
		                        		
		                        		
		                        		
		                        	
9.High-throughput sequencing for confirmation of suspected 2019-nCoV infection identified by fluorescence quantitative polymerase chain reaction.
Wen-Da GUAN ; Li-Ping CHEN ; Feng YE ; Dan YE ; Shi-Guan WU ; Hong-Xia ZHOU ; Jia-Yang HE ; Chun-Guang YANG ; Zhi-Qi ZENG ; Yu-Tao WANG ; Run-Feng LI ; Qiu-Ling DU ; Xiao-Li LIANG ; Qin-Hai MA ; Zi-Feng YANG
Chinese Medical Journal 2020;133(11):1385-1386
10. Consensus on standardized diagnosis and treatment for osteoporotic vertebral compression fracture patients during epidemic of corona virus disease 2019
Zhong FANG ; Baorong HE ; Dingjun HAO ; Feng LI ; Liang YAN ; Yanzheng GAO ; Shiqing FENG ; Tiansheng SUN ; Dianming JIANG ; Jiwei TIAN ; Huan WANG ; Yingze ZHANG ; Shunwu FAN ; Yue ZHU ; Yijian LIANG ; Yun TIAN ; Bo LI ; Weimin JIANG ; Jingye WANG ; Xiaohui MAO ; Changsheng ZHU ; Yali LI ; Lijun HE ; Yuan HE ; Qindong SHI ; Shuixia LI ; Jing WANG ; Zijun GAO ; Buhuai DONG ; Honghui YU ; Yonghong JIANG
Chinese Journal of Trauma 2020;36(2):117-123
		                        		
		                        			
		                        			 Since December 2019, the corona virus disease 2019 (COVID-19) caused by the 2019 novel coronavirus (2019-nCoV) has been reported in Wuhan, Hubei Province. Almost 70% of patients susceptible to 2019-nCoV are over age of 50 years, with extremely large proportion of critical illness and death of the elderly patients. Meanwhile, the elderly patients are at high risk of osteoporotic fractures especially osteoporotic vertebral compression fractures (OVCF). During the prevention and control of COVID-19 epidemic, orthopedists are confronted with the following difficulties including how to screen and protect OVCF patients, how to accurately diagnose and assess the condition of OVCF patients with suspected or confirmed COVID-19, and how to develop reasonable treatment plans and comprehensive protective measures in emergency and outpatient clinics. In order to standardize the diagnosis and treatment of patients with OVCF diagnosed with COVID-19, the authors jointly develop this expert consensus. The consensus systematically recommends the standardized emergency and outpatient screening and confirmation procedures for OVCF patients with suspected or confirmed COVID-19 and protective measures for emergency and outpatient clinics. Moreover, the consensus describes the grading and classification of OVCF patients diagnosed with COVID-19 according to the severity of illness and recommends different treatment plans and corresponding protective measures based on the different types and epidemic prevention and control requirements. 
		                        		
		                        		
		                        		
		                        	
            
Result Analysis
Print
Save
E-mail